UBS Group’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
UBS Group's AGMB Position: Q3 2026 in Review
UBS Group increased its AgomAb Therapeutics NV (AGMB) stake by 2,321% in Q3 2026, buying an estimated $639K and bringing the position to 51,516 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #6102.
UBS Group first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- UBS Group held 51,516 shares of AgomAb Therapeutics NV worth $572K as of Q3 2026.
- UBS Group bought 49,388 AgomAb Therapeutics NV shares in Q3 2026, an estimated $639K.
- AgomAb Therapeutics NV made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6102 holding.
- UBS Group first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.